BIOA combines a highly favorable modeled asymmetry and strong revenue growth with severe cash burn and a business quality score far below the engine's floor, alongside an overbought technical setup and a recent earnings miss streak.
Thesis pillars
- Quality Far Below Floor Cash Burn→Stable
- High Asymmetry Analyst Upside→Stable
- Strong Revenue Growth→Stable
- +2 more pillars — see the Why tab for full reasoning
BioAge Labs, Inc. (BIOA) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $23.91: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 5.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases by targeting human aging biology, using a proprietary platform spanning over 150 million molecular data points from more than 25,000 participants tracked for up to 50 years.... Read more
Sell if holding. Engine safety override at $23.91: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 5.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Score 6.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About BioAge Labs, Inc.
About BioAge Labs, Inc.
BioAge Labs' pipeline centers on BGE-102, an oral, brain-penetrant NLRP3 inhibitor now completing Phase 1 SAD/MAD dosing with full data expected in the first half of 2026, targeted at both cardiometabolic disease and diabetic macular edema. In a January 2026 interim readout, BGE-102 produced an 86% median reduction in hsCRP at Day 14 among obese participants with elevated cardiovascular risk, with a Phase 2a proof-of-concept trial planned for the first half of 2026. BioAge held $285.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
BioAge has no approved products or product revenue, funding its pipeline through equity financing and instead building revenue potential through platform collaborations: an ongoing target-discovery partnership with Novartis Pharma AG, an early-stage program collaboration with Eli Lilly and Company, and a June 2025 option agreement with JiKang Therapeutics covering a novel APJ agonist antibody for obesity. Beyond BGE-102, the company is developing oral and injectable apelin receptor APJ agonists that in preclinical obesity models more than doubled the weight loss achieved by a GLP-1 receptor agonist alone, with the first IND filing for an APJ program targeted by year-end 2026. BioAge's approach differs from competitors pursuing injectable anti-inflammatory antibodies for cardiovascular risk reduction by using once-daily oral dosing, and the company plans to selectively partner product candidates given the global GLP-1 receptor agonist market's projected growth to $150 billion by 2031.
Show full overview
BioAge's near-term prospects concentrate heavily on a single asset: the 10-K states the company depends entirely on the success of a limited number of product candidates, and its former lead candidate, azelaprag, was discontinued from Phase 2 testing in December 2024 after some subjects developed liver transaminitis. With cash and marketable securities of $285.1 million expected to fund operations only through 2029, BGE-102's Phase 2a cardiometabolic and Phase 1b/2a ophthalmology readouts due by late 2026 and mid-2027, respectively, represent binary catalysts that will largely determine whether that runway needs to be extended before either program reaches a pivotal trial.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From BioAge Labs, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.91: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 5.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Prior stop was $21.98. Score 6.3/10, moderate confidence.
Take-profit target: $43.06 (+82.2% upside). Prior stop was $21.98. Stop-loss: $21.98.
Quality below floor (1.9 < 4.0).
BioAge Labs, Inc. trades at a P/E of N/A (forward -12.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover BIOA with a consensus score of 4.2/5. Average price target: $50.
What does BioAge Labs, Inc. do?BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases by targeting...
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases by targeting human aging biology, using a proprietary platform spanning over 150 million molecular data points from more than 25,000 participants tracked for up to 50 years. Its lead program, BGE-102, is an oral NLRP3 inhibitor in development for cardiometabolic disease and diabetic macular edema. The company reported an $80.6 million net loss in 2025 and held $285.1 million in cash and marketable securities as of December 31, 2025.